Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Talaulikar, Dipti; Tam, Constantine S; Joshua, Douglas; Ho, Joy Phoebe; Szer, Jeff; Quach, Hang; Spencer, Andrew; Harrison, Simon; Mollee, Peter; Roberts, Andrew W; Horvath, Noemi; Lee, Cindy; Zannettino, Andrew; Brown, Ross; Augustson, Bradley; Jaksic, Wilfrid; Gibson, John; Kalff, Anna; Johnston, Anna; Trotman, Judith; Kalro, Akash; Grigoriadis, George; Ward, Chris; Prince, H Miles
Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is...[Show more]
|Collections||ANU Research Publications|
|Source:||Internal medicine journal|
|01_Talaulikar_Treatment_of_patients_2017.pdf||705.81 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.